Publication details
Postavení warfarinu v současnosti: potřebujeme ještě vitamin K antagonisty?
| Title in English | Present role of warfarin: do we still need vitamin K antagonists? |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Postgraduální medicína |
| MU Faculty or unit | |
| Citation | |
| Keywords | hypercoagulable states; warfarin; new antithrombotics; fondaparinux; idraparinux; dabigatran; rivaroxaban; apixaban; edoxaban |
| Description | The hypercoagulable states belong among the most frequent causes of morbidity and mortality in the developed ountries worldwide. The hemostasis plays an important role not only in stopping of bleeding, but takes part also in immunity, wound healing, and in the processes of growing, progression, and metastasing of malignant tumors. This is the cause why many research teams pay great attention to the problematics of hemostasis, including the development of new antithrombotic drugs. The hemostasis is being explored in details on many levels, creating so the basis of developing and testing of new drugs in both the preclinical and clinical trials. The most promising drugs at present represent the pentasaccharides, the direct inhibitors of factor Xa, and the direct inhibitors of thrombin. It may be expected, that these new antithrombotics replace the classic drugs (heparins and vitamin K antagonists) in the prevention and treatment of thrombosis in both the venous and arterial circulation. Aim of our work is to illustrate recent indications for vitamin K antagonists in the era of new anticoagulants. |